Compare Eli Lilly And Co (LLY) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Skyworks Solutions Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Skyworks Solutions Inc trades at $76.35 (market cap $12.15B). The key difference: Eli Lilly And Co is far larger — about 85.6× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Skyworks Solutions Inc for 50 Days on average.
| LLY | SWKS | |
|---|---|---|
Market Cap | $1.04T | $12.15B |
Volume | 3,064,878 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $1.28K | $91.45 |
52-Week Low | $799.57 | $52.50 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | $12.03B |
Dividend Yield | 0.59% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Skyworks Solutions (SWKS) trades at $80.75, down 3.21% today, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.1M. Key developments include the pending Qorvo merger, which has driven recent volatility and analyst optimism about potential synergies.
The investment outlook is mixed: strong analyst support (60% buy ratings) and merger potential offer upside, but declining fundamentals and bearish technicals present near-term risks. The consensus price target of $78.80 suggests limited upside from current levels, making careful monitoring of merger progress and Q3 earnings crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
